Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “T Lymphocyte Receptor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT03139370
What this trial is testing

Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers

Who this might be right for
Solid Tumor
Kite, A Gilead Company 16
Not applicableNot Yet RecruitingNCT06142188
What this trial is testing

Relmacabtagene Autoleucel in Hematologic Malignancies

Who this might be right for
Lymphoma, B-CellLarge B-cell LymphomaFollicular Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd. 150
Testing effectiveness (Phase 2)Looking for participantsNCT03579875
What this trial is testing

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

Who this might be right for
Fanconi AnemiaSevere Aplastic AnemiaMyelodysplastic Syndromes+5 more
Masonic Cancer Center, University of Minnesota 48
Not applicableUnknownNCT03380039
What this trial is testing

Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma

Who this might be right for
Refractory or Relapsed Multiple Myeloma
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 6
Early research (Phase 1)UnknownNCT05210907
What this trial is testing

Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Seoul National University Hospital 5
Testing effectiveness (Phase 2)Looking for participantsNCT03412877
What this trial is testing

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Who this might be right for
Endocrine TumorsNon-Small Cell Lung CancerOvarian Cancer+4 more
National Cancer Institute (NCI) 285
Early research (Phase 1)WithdrawnNCT06290622
What this trial is testing

PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL

Who this might be right for
Diffuse Large B Cell LymphomaLymphoma, B-CellLymphoma, Follicular
University of Alabama at Birmingham
Early research (Phase 1)Study completedNCT03338972
What this trial is testing

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Fred Hutchinson Cancer Center 28
Early research (Phase 1)Study completedNCT02592577
What this trial is testing

MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC

Who this might be right for
Non-Small Cell Lung CancerCarcinoma
Adaptimmune 28
Early research (Phase 1)Study completedNCT00085930
What this trial is testing

Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients

Who this might be right for
Neuroblastoma
Baylor College of Medicine 19
Early research (Phase 1)Looking for participantsNCT07594067
What this trial is testing

TCR1188-ABC Cells in KRAS-mutated Cancers

Who this might be right for
CholangiocarcinomaColorectal CancerNon-Small Cell Lung Cancer+1 more
University of Pennsylvania 30
Early research (Phase 1)Looking for participantsNCT07572136
What this trial is testing

Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Who this might be right for
B-AllAcute Lymphoblastic Leukemia
National Cancer Institute (NCI) 57
Early research (Phase 1)Active Not RecruitingNCT05753501
What this trial is testing

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Who this might be right for
Hematologic Cancer
AbbVie 135
Early research (Phase 1)Active Not RecruitingNCT05539430
What this trial is testing

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma

Who this might be right for
Gastric CancerGastroesophageal-junction CancerEsophageal Cancer+1 more
Legend Biotech USA Inc 56
Early research (Phase 1)UnknownNCT03298828
What this trial is testing

CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

Who this might be right for
Acute Lymphoblastic LeukemiaBurkitt Lymphoma
Third Military Medical University 30
Testing effectiveness (Phase 2)Study completedNCT03373071
What this trial is testing

Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL

Who this might be right for
CD19-ALLCD19-LNH
Bambino Gesù Hospital and Research Institute 29
Testing effectiveness (Phase 2)Looking for participantsNCT06585514
What this trial is testing

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus

Who this might be right for
Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)
Beijing GoBroad Hospital 18
Early research (Phase 1)Study completedNCT03602612
What this trial is testing

T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma

Who this might be right for
Myeloma-MultipleMyeloma, Plasma-Cell
National Cancer Institute (NCI) 35
Early research (Phase 1)Ended earlyNCT03126864
What this trial is testing

Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia

Who this might be right for
Hematopoietic/Lymphoid CancerAcute Myeloid Leukemia
M.D. Anderson Cancer Center 11
Testing effectiveness (Phase 2)Study completedNCT03548207
What this trial is testing

JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 126
Next Page